Free Trial

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down - Here's Why

Shionogi & Co., Ltd. Unsponsored ADR logo with Medical background

Key Points

  • Shionogi & Co., Ltd. Unsponsored ADR shares experienced a significant gap down, opening at $8.31 compared to the previous close of $8.82, with a trading volume of 2,045 shares.
  • The company reported a quarterly earnings per share of $0.16, surpassing analyst expectations of $0.14, but its revenue was lower than expected at $672.90 million against estimates of $719.55 million.
  • Shionogi maintains a strong financial position with a debt-to-equity ratio of 0.01 and notable current and quick ratios, suggesting robust liquidity.
  • Need better tools to track Shionogi & Co., Ltd. Unsponsored ADR? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $8.82, but opened at $8.31. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.31, with a volume of 2,045 shares.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 2.6%

The firm has a market cap of $14.55 billion, a P/E ratio of 14.20, a P/E/G ratio of 1.90 and a beta of 0.20. The firm has a fifty day moving average of $8.50 and a 200-day moving average of $7.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.13 and a current ratio of 6.63.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last issued its earnings results on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.02. The firm had revenue of $672.90 million during the quarter, compared to analyst estimates of $719.55 million. Equities research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

(Get Free Report)

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

See Also

Should You Invest $1,000 in Shionogi & Co., Ltd. Unsponsored ADR Right Now?

Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list.

While Shionogi & Co., Ltd. Unsponsored ADR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines